RTX 001 - Resolution Therapeutics
Alternative Names: RTX-001 - Resolution TherapeuticsLatest Information Update: 09 Oct 2024
At a glance
- Originator Resolution Therapeutics
- Class Anti-inflammatories; Antifibrotics; Cell therapies; Gene therapies
- Mechanism of Action Macrophage replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Liver cirrhosis
Most Recent Events
- 03 Oct 2024 Resolution Therapeutics plans the phase I/II EMERALD trial for Liver cirrhosis in United Kingdom and Spain (IV) in fourth quarter of 2024
- 27 Jun 2024 UK Medicines and Healthcare products Regulatory Agency (MHRA) approves clinical trial application for RTX 001, to initiate the phase I/II EMERALD trial in Liver cirrhosis
- 20 Jun 2024 Adverse events data from a phase I/II trial in Liver cirrhosis presented at the European Association for the Study of the Liver Congress 2024 (EASL-2024)